List view / Grid view
8 May 2015 | By Victoria White
The Asia-Pacific treatment market for psoriasis will almost double in value, from $690 million in 2014 to $1.2 billion by 2021, representing a CAGR of 8.4%...
7 May 2015 | By Victoria White
Ohr Pharmaceutical presented the results from the Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet-AMD at ARVO...
7 May 2015 | By kdm communications
Operating capacity set to more than double in response to rising demand...
7 May 2015 | By Victoria White
The Bill & Melinda Gates Foundation are set to announce CHAMPS - a network of disease surveillance sites in developing countries...
7 May 2015 | By Victoria White
J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...
7 May 2015 | By Victoria White
Alexion Pharmaceuticals has announced that it is set to acquire Synageva BioPharma in a transaction valued at approximately $8.4 billion...
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
7 May 2015 | By
A 7-year study of a Nulojix regimen has demonstrated a significant relative risk reduction of death or transplant failure over a cyclosporine regimen...
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
6 May 2015 | By Victoria White
GSK, Telethon and OSR have submitted a marketing application to the EMA for a gene therapy to treat patients with a rare disease, ADA-SCID...
6 May 2015 | By Victoria White
Teva has acquired Auspex Pharmaceuticals through the successful tender offer for all of the outstanding Auspex shares at $101.00 per share...
6 May 2015 | By Victoria White
Lilly is set to establish a new drug delivery and device innovation centre in Cambridge, increasing its delivery and devise R&D space by almost 50%...
6 May 2015 | By Victoria White
Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia...
6 May 2015 | By
Acacia Pharma has announced positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV)...
6 May 2015 | By Victoria White
NDA Group's new Infographic looks at drug approvals in 2014 and highlights the fact that nearly 40% of approved products came from non top pharma companies...
